Innoventric Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
22
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$28.5M
- Investors
-
8
Innoventric General Information
Description
Developer of percutaneous devices designed to provide treatment of tricuspid regurgitation. The company's device offers functional tricuspid valve replacement that utilizes Cross-Caval anchoring and a unique multi-valve design, for long-lasting blood flow regulation, enabling patients to improve their lifespan and quality of life.
Contact Information
Website
www.innoventric.comCorporate Office
- 1 Chaim Holzman Street
- Rehovot
- Israel
Corporate Office
- 1 Chaim Holzman Street
- Rehovot
- Israel
Innoventric Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series B) | 29-Oct-2024 | $28.5M | Completed | Generating Revenue | ||
| 4. Later Stage VC (Series A) | 01-Nov-2021 | Completed | Clinical Trials - General | |||
| 3. Grant | 16-Jun-2021 | Completed | Generating Revenue | |||
| 2. Seed Round | 14-Apr-2019 | $3.5M | $4.25M | Completed | Clinical Trials - General | |
| 1. Seed Round | 01-Jan-2017 | $745K | $745K | Completed | Clinical Trials - General |
Innoventric Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferred B-1 | ||||||||
| Series A | ||||||||
| Preferred Seed 2 | 2,060,936 | $0.010000 | $1.7 | $1.7 | 1x | $1.7 | 20.52% | |
| Preferred Seed1 | 512,654 | $0.010000 | $1.45 | $1.45 | 1x | $1.45 | 5.1% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Innoventric Patents
Innoventric Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026115550-A1 | Systems, methods and devices for treating tricuspid insufficiency | Pending | 27-Nov-2024 | ||
| WO-2026013677-A1 | Medical implant storage apparatus | Pending | 11-Jul-2024 | ||
| AU-2023369556-A1 | Systems, methods, and devices for treating a diseased or otherwise damaged tricuspid valve | Pending | 24-Oct-2022 | ||
| EP-4608332-A1 | Systems, methods, and devices for treating a diseased or otherwise damaged tricuspid valve | Pending | 24-Oct-2022 | ||
| EP-4608332-A4 | Systems, methods, and devices for treating a diseased or otherwise damaged tricuspid valve | Pending | 24-Oct-2022 | A61F2/2418 |
Innoventric Signals
Innoventric Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Mivtach Shamir Holdings | PE/Buyout | Minority | ||
| RA Capital Management | Asset Manager | Minority | ||
| European Commission | Government | Minority | ||
| JG Investment | PE/Buyout | Minority | ||
| European Innovation Council | Accelerator/Incubator | Minority |
Innoventric FAQs
-
When was Innoventric founded?
Innoventric was founded in 2016.
-
Where is Innoventric headquartered?
Innoventric is headquartered in Rehovot, Israel.
-
What is the size of Innoventric?
Innoventric has 22 total employees.
-
What industry is Innoventric in?
Innoventric’s primary industry is Therapeutic Devices.
-
Is Innoventric a private or public company?
Innoventric is a Private company.
-
What is the current valuation of Innoventric?
The current valuation of Innoventric is .
-
What is Innoventric’s current revenue?
The current revenue for Innoventric is .
-
How much funding has Innoventric raised over time?
Innoventric has raised $44.2M.
-
Who are Innoventric’s investors?
Mivtach Shamir Holdings, RA Capital Management, European Commission, JG Investment, and European Innovation Council are 5 of 8 investors who have invested in Innoventric.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process